Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS: We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS: During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS: Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016-002299-28.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Compared with placebo, OM reduced incidence of the primary outcome over 22 months of follow-up (37.0% vs 39.1%; HR, 0.92 [95% CI 0.85-0.99]).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [72]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationRegularization Paths for Cox's Proportional Hazards Model via Coordinate Descent
Simon, N., Friedman, J., Hastie, T., & Tibshirani, R. (2011) · Journal of Statistical Software · doi:10.18637/jss.v039.i05 · Cited by 2,499
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.033502 · Cited by 750
Self-citationCardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure
Malik, F. I., Hartman, J. J., Elias, K. A., Morgan, B. P., Rodriguez, H., Brejc, K., Anderson, R. L., Sueoka, S. H., Lee, K. H., Finer, J. T., et al. (2011) · Science · doi:10.1126/science.1200113 · Cited by 584
Self-citationRepeated assessment of results in clinical trials of cancer treatment
Haybittle, J. L. (1971) · The British Journal of Radiology · doi:10.1259/0007-1285-44-526-793 · Cited by 517
Kramer, D. G., Trikalinos, T. A., Kent, D. M., Antonopoulos, G. V., Konstam, M. A., & Udelson, J. E. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.011 · Cited by 492
Cited by
Items 101–200 of 709
Advances in management of heart failure
Heidenreich, P. A., & Sandhu, A. T. (2024) · BMJ · doi:10.1136/bmj-2023-077025 · Cited by 43
Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping
Dimond, M. G., Ibrahim, N. E., Fiuzat, M., McMurray, J. J. V., Lindenfeld, J. M., Ahmad, T., Bozkurt, B., Bristow, M. R., Butler, J., Carson, P. E., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.11.005 · Cited by 41
Self-citationPharmacologic Treatment of Heart Failure With Reduced Ejection Fraction
van Essen, B. J., Ceelen, D. C. H., Ouwerkerk, W., Teng, T. K., Tharshana, G. N., Hew, F. M., Butler, J., Zannad, F. M., Lam, C. S. P., Ezekowitz, J. A., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.054 · Cited by 41
Self-citationWinkle, P. J., Goldsmith, S. R., Koren, M. J., Lepage, S., Hellawell, J. L., Trivedi, A., Tsirtsonis, K., Abbasi, S. A., Kaufman, A., Troughton, R. W., et al. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07328-w · Cited by 40
Self-citationMetra, M., Pagnesi, M., Claggett, B. L., Díaz, R., Felker, G. M., McMurray, J. J. V., Solomon, S. D., Bonderman, D., Fang, J. C.-T., Fonseca, C., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac293 · Cited by 39
Self-citationRecent advances in pharmacological treatment of heart failure
Iacoviello, M., Palazzuoli, A., & Gronda, E. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13624 · Cited by 39
Neues zur Diagnostik und Therapie der Herzinsuffizienz
Wintrich, J., Berger, A.-K., Bewarder, Y., Emrich, I. E., Slawik, J., & Böhm, M. (2021) · Herz · doi:10.1007/s00059-021-05062-x · Cited by 41
Self-citationTreatment of HF in an Era of Multiple Therapies
Bhatt, A. S., Abraham, W. T., Lindenfeld, J., Bristow, M. R., Carson, P. E., Felker, G. M., Fonarow, G. C., Greene, S. J., Psotka, M. A., Solomon, S. D., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.10.014 · Cited by 38
Self-citationThe Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
Koutentakis, M., Kuciński, J., Świeczkowski, D., Surma, S., Filipiak, K. J., & Gąsecka, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10110465 · Cited by 38
Olivotto, I., Udelson, J. E., Pieroni, M., & Rapezzi, C. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac764 · Cited by 38
Ortíz, A., Navarro‐González, J. F., Núñez, J. E., de la Espriella, R., Cobo, M., Santamaría, R., de Sequera, P., & Díez, J. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab290 · Cited by 38
Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction
Saldarriaga, C., Atar, D., Stebbins, A., Lewis, B. S., Abidin, I. Z., Blaustein, R. O., Butler, J., Ezekowitz, J. A., Hernandez, A. F., Lam, C. S. P., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2468 · Cited by 38
Self-citationComplexity in genetic cardiomyopathies and new approaches for mechanism-based precision medicine
Greenberg, M. J., & Tardiff, J. C. (2021) · The Journal of General Physiology · doi:10.1085/jgp.202012662 · Cited by 37
Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies
Lala, A., HAMO, C. E., Bozkurt, B., Fiuzat, M., Blumer, V. L., Bukhoff, D., Butler, J., Costanzo, M. R., Felker, G. M., Filippatos, G. S., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.09.030 · Cited by 37
Self-citationRecent and Upcoming Drug Therapies for Pediatric Heart Failure
Loss, K. L., Shaddy, R. E., & Kantor, P. F. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.681224 · Cited by 36
Kassis-George, H., Verlinden, N. J., Fu, S., & Kanwar, M. (2022) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s357422 · Cited by 35
Heart failure population health considerations
Patel, J. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88673 · Cited by 35
Acute Heart Failure and Iron Deficiency: A Prospective, Multicentre, Observational Study
van Dalen, D. H., Kragten, J. A., Emans, M. E., van Ofwegen-Hanekamp, C. E. E., Klaarwater, C., Spanjers, M. H. A., Hendrick, R., van Deursen, C. T. B. M., & Rocca, H. B. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13737 · Cited by 35
Recent Developments in the Evaluation and Management of Cardiorenal Syndrome: A Comprehensive Review
Kim, J. A., Wu, L., Rodriguez, M., Lentine, K. L., Virk, H. U. H., Hachem, K. E., Lerma, E. V., Kiernan, M. S., Rangaswami, J., & Krittanawong, C. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101509 · Cited by 34
Meller, A., Lotthammer, J. M., Smith, L. G., Novak, B., Lee, L. A., Kuhn, C. C., Greenberg, L., Leinwand, L. A., Greenberg, M. J., & Bowman, G. R. (2023) · eLife · doi:10.7554/elife.83602 · Cited by 34
Shen, S. H., Sewanan, L. R., Jacoby, D. L., & Campbell, S. G. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.020860 · Cited by 34
Cardiac Organoids to Model and Heal Heart Failure and Cardiomyopathies
Seguret, M., Vermersch, E., Jouve, C., & Hulot, J. (2021) · Biomedicines · doi:10.3390/biomedicines9050563 · Cited by 33
Ameri, P., Bertero, E., Maack, C., Teerlink, J. R., Rosano, G. M. C., & Metra, M. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab033 · Cited by 33
Self-citationEmerging Medical Treatment for Hypertrophic Cardiomyopathy
Argirò, A., Zampieri, M., Berteotti, M., Marchi, A. G., Tassetti, L., Zocchi, C., Iannone, L., Bacchi, B., Cappelli, F., Stefàno, P., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10050951 · Cited by 33
NT-proBNP Response to Heart Failure Therapies
Cunningham, J. W., & Myhre, P. L. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.045 · Cited by 33
Advanced heart failure: from definitions to therapeutic options
Garascia, A., Palazzini, M., Tedeschi, A., Sacco, A., Oliva, F. G., & Gentile, P. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad028 · Cited by 33
Verma, S., Anker, S. D., Butler, J., & Bhatt, D. L. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13148 · Cited by 32
Ilyas, F., Jones, L., Tee, S. L., Horsfall, M. J., Swan, A., Wollaston, F., Hecker, T., Pasquale, C. D., Thomas, S., Chong, W., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13553 · Cited by 32
Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy
Zampieri, M., Argirò, A., Marchi, A. G., Berteotti, M., Targetti, M., Fornaro, A., Tomberli, A., Stefàno, P., Marchionni, N., & Olivotto, I. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01508-0 · Cited by 32
Moghaddam, N., Hawkins, N. M., McKelvie, R. S., Poon, S., Joncas, S. X., MacFadyen, J. R., Honos, G. N., Wang, J., Rojas‐Fernandez, C. H., Kok, M., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2022.10.013 · Cited by 31
Huang, G., Bisaria, A., Wakefield, D. L., Yamawaki, T., Luo, X., Zhang, J. A., Vigneault, P., Wang, J., Reagan, J. D., Oliverio, O., et al. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.11.008 · Cited by 31
Self-citationChiang, C., Hung, C., Wu, Y., Lin, T., Ueng, K., Sung, S., Wu, C., Chao, T., Lin, H., Lin, Y., et al. (2023) · PubMed Central · doi:10.6515/acs.202305_39(3).20230301a · Cited by 30
MacDonald, B. J., Virani, S., Zieroth, S. R., & Turgeon, R. D. (2023) · CJC Open · doi:10.1016/j.cjco.2023.05.008 · Cited by 30
Novel insights into sarcomere regulatory systems control of cardiac thin filament activation
Solís, C., & Solaro, R. J. (2021) · The Journal of General Physiology · doi:10.1085/jgp.202012777 · Cited by 30
Omecamtiv mecarbil evokes diastolic dysfunction and leads to periodic electromechanical alternans
Fülöp, G. Á., Oláh, A., Csípő, T., Kov́acs, Á., Pórszász, R., Veress, R., Horváth, B., Nagy, L., Bódi, B., Fagyas, M., et al. (2021) · Basic Research in Cardiology · doi:10.1007/s00395-021-00866-8 · Cited by 30
Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial
Pabón, M. A., Cunningham, J. W., Claggett, B. L., Felker, G. M., McMurray, J. J. V., Metra, M., Díaz, R., Wang, X., Arias‐Mendoza, A., Bonderman, D., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.07.029 · Cited by 30
Self-citationJani, V., Aslam, M. I., Fenwick, A. J., Ma, W., Gong, H. M., Milburn, G. N., Nissen, D. L., Salazar, I. M. C., Hanselman, O., Mukherjee, M., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.064717 · Cited by 30
Kansakar, U., Varzideh, F., Jankauskas, S. S., Gambardella, J., Trimarco, B., & Santulli, G. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab069 · Cited by 29
Mechanisms of Sarcomere Protein Mutation-Induced Cardiomyopathies
Barefield, D. Y., Álvarez-Arce, A., & Araujo, K. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01876-9 · Cited by 29
Hitsumoto, T., Tsukamoto, O., Matsuoka, K., Li, J., Liu, L., Kuramoto, Y., Higo, S., Ogawa, S., Fujino, N., Yoshida, S., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.062885 · Cited by 29
Self-citationDaniels, M. J., Fusi, L., Semsarian, C., & Naidu, S. S. (2021) · Circulation · doi:10.1161/circulationaha.121.056324 · Cited by 29
Aimo, A., Castiglione, V., Vergaro, G., Panichella, G., Senni, M., Lombardi, C., & Emdin, M. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10146-1 · Cited by 28
Treatment Strategies of Improving Quality of Care in Patients With Heart Failure
Kim, S.-E., & Yoo, B. (2023) · Korean Circulation Journal · doi:10.4070/kcj.2023.0024 · Cited by 28
Inotropic therapies in heart failure and cardiogenic shock: an educational review
DesJardin, J. T., & Teerlink, J. R. (2021) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuab047 · Cited by 28
Self-citationLewis, G. D., Docherty, K. F., Voors, A. A., Solal, A. C., Metra, M., Whellan, D. J., Ezekowitz, J. A., Ponikowski, P. P., Böhm, M., Teerlink, J. R., et al. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008970 · Cited by 28
Self-citationTricuspid Regurgitation and Clinical Outcomes in Heart Failure With Reduced Ejection Fraction
Adamo, M., Metra, M., Claggett, B. L., Miao, Z. M., Díaz, R., Felker, G. M., McMurray, J. J. V., Solomon, S. D., Biering‐Sørensen, T., Divanji, P., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2023.11.018 · Cited by 28
Self-citationTargeting mitochondrial dysfunction with elamipretide
Obi, C., Smith, A. T., Hughes, G. J., & Adeboye, A. A. (2022) · Heart Failure Reviews · doi:10.1007/s10741-021-10199-2 · Cited by 27
Danielson, C., Lileikyte, G., Ouwerkerk, W., Lam, C. S. P., Erlinge, D., & Teng, T. K. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13974 · Cited by 27
Saldarriaga, C., Zannad, F. M., McMullan, C. J., Xing, A., Gates, D. F., Anstrom, K. J., Bonaca, M. P., Corda, S., Ezekowitz, J. A., Lam, C. S. P., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3598 · Cited by 27
Self-citationHe, H., Baka, T., Balschi, J., Motani, A. S., Nguyen, K. K., Liu, Q., Slater, R., Rock, B., Wang, C., Hale, C. M., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.009195 · Cited by 27
Self-citationPractical Patient Care Considerations With Use of Vericiguat After Worsening Heart Failure Events
Rao, V. N., Díez, J., Gustafsson, F., Mentz, R. J., Senni, M., Jankowska, E. A., & Bauersachs, J. K. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.10.431 · Cited by 26
Medical Management of Patients With Heart Failure and Reduced Ejection Fraction
Greenberg, B. (2022) · Korean Circulation Journal · doi:10.4070/kcj.2021.0401 · Cited by 26
Johansen, N. D., Vaduganathan, M., Zahir, D., Fiuzat, M., DeFilippis, E. M., Januzzi, J. L., Butler, J., O’Connor, C. M., Abraham, W. T., Psotka, M. A., et al. (2023) · Circulation Heart Failure · doi:10.1161/circheartfailure.122.009729 · Cited by 26
Self-citationKasprzak, J. D., Gorczyca-Głowacka, I., Sobczak, M., Barylski, M., Dróżdż, J., Filipiak, K. J., Kapłon‐Cieślicka, A., Lelonek, M., Mamcarz, A., Ochijewicz, D., et al. (2023) · Kardiologia Polska · doi:10.33963/kp.a2023.0110 · Cited by 26
Ducharme, A., Zieroth, S. R., Ahooja, V., Anderson, K., Andrade, J. G., Boivin‐Proulx, L., Ezekowitz, J. A., Howlett, J. G., Lepage, S., Leong, D., et al. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.04.022 · Cited by 25
Self-citationWorsening heart failure: progress, pitfalls, and perspectives
Fonseca, C., Rui, B., Franco, F., Brenda, M., Pimenta, J., Sarmento, P., Silva‐Cardoso, J., & Brito, D. A. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10497-z · Cited by 26
Self-citationPathophysiology of Advanced Heart Failure
Biegus, J., Niewiński, P., Josiak, K., Kulej, K., Ponikowska, B., Nowak, K., Zymliński, R., & Ponikowski, P. P. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.06.001 · Cited by 25
Self-citationZhang, S., Shu, H., Zhou, J., Rubin-Sigler, J., Yang, X. J., Liu, Y., Cooper‐Knock, J., Monte, E., Zhu, C., Tu, S., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02725-6 · Cited by 25
Stogios, N., Fezza, G. C., Wong, J. Y. L., Ross, H. J., Farkouh, M. E., & Nolan, R. P. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2139 · Cited by 25
Timely and individualized heart failure management: need for implementation into the new guidelines
Abdin, A., Bauersachs, J. K., Frey, N., Kindermann, I., Link, A., Marx, N., Lainščak, M., Slawik, J., Werner, C. M., Wintrich, J., et al. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-021-01867-2 · Cited by 24
Self-citationJering, K., Campagnari, C., Claggett, B. L., ADLER, E. D., Klein, L., Ahmad, F. S., Voors, A. A., Solomon, S. D., Yagil, A., & Greenberg, B. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2528 · Cited by 24
Self-citationVolterrani, M., Hálasz, G., Adamopoulos, S. N., Agostoni, P., Butler, J., Coats, A. J. S., Solal, A. C., Doehner, W., Filippatos, G., Jankowska, E. A., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3440 · Cited by 24
Self-citationContemporary Pillars of Heart Failure with Reduced Ejection Fraction Medical Therapy
Rahamim, E., Nachman, D., Yagel, O., Yarkoni, M., Elbaz‐Greener, G., Amir, O., & Asleh, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194409 · Cited by 24
Evidence-based Therapy in Older Patients with Heart Failure with Reduced Ejection Fraction
Stolfo, D., Sinagra, G., & Savarese, G. (2022) · Cardiac failure review · doi:10.15420/cfr.2021.34 · Cited by 24
Merkaš, I. S., Slišković, A. M., & Lakušić, N. (2021) · World Journal of Cardiology · doi:10.4330/wjc.v13.i7.183 · Cited by 23
Solomon, S. D., Claggett, B. L., Miao, Z. M., Díaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Corbalan, R. L., Filippatos, G. S., Goudev, A., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac144 · Cited by 23
Self-citationPDE1 Inhibition Modulates Ca v 1.2 Channel to Stimulate Cardiomyocyte Contraction
Muller, G. K., Song, J., Jani, V., Wu, Y., Liu, T., Jeffreys, W. P. D., O'Rourke, B. P., Anderson, M. E., & Kass, D. A. (2021) · Circulation Research · doi:10.1161/circresaha.121.319828 · Cited by 23
Congestion in Patients with Advanced Heart Failure
Lombardi, C., Cimino, G., Pellicori, P., Bonelli, A., Inciardi, R. M., Pagnesi, M., Tomasoni, D., Ravera, A., Adamo, M., Carubelli, V., et al. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.05.003 · Cited by 23
Self-citationMechanisms of current therapeutic strategies for heart failure: more questions than answers?
Khan, M. S., Shahid, I., Greene, S. J., Mentz, R. J., DeVore, A. D., & Butler, J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac187 · Cited by 22
Volterrani, M., Hálasz, G., Adamopoulos, S. N., Agostoni, P., Butler, J., Coats, A. J. S., Solal, A. C., Doehner, W., Filippatos, G., Jankowska, E. A., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad400 · Cited by 22
Self-citationDas, B. B., Moskowitz, W. B., & Butler, J. (2021) · Children · doi:10.3390/children8050322 · Cited by 22
Differential Proteomics of Cardiovascular Risk and Coronary Artery Disease in Humans
Ferrannini, E., Manca, M. L., Ferrannini, G., Andreotti, F., Andreini, D., Latini, R., Magnoni, M., Williams, S. A., Maseri, A., & Maggioni, A. P. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.790289 · Cited by 22
Heart failure in children and adolescents: an update on diagnostic approaches and management
Agrawal, A., Janjua, D., Zeyada, A. A., & Elsheikh, A. T. (2023) · Korean Journal of Pediatrics · doi:10.3345/cep.2023.00528 · Cited by 22
Shakoor, A., Kamar, S. A., Malgie, J., Kardys, I., Schaap, J., de Boer, R. A., Mieghem, N. M. V., van der Boon, R. M. A., & Brugts, J. J. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3048 · Cited by 21
New Therapeutics for Heart Failure: Focusing on cGMP Signaling
Mangmool, S., Duangrat, R., Parichatikanond, W., & Kurose, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612866 · Cited by 21
The Role of sGC Stimulators and Activators in Heart Failure With Reduced Ejection Fraction
Cordwin, D. J., Berei, T. J., & Pogue, K. T. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211042706 · Cited by 21
Getting ahead of the game: in-hospital initiation of HFrEF therapies
Biegus, J., Moayedi, Y., Saldarriaga, C., & Ponikowski, P. P. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suac120 · Cited by 21
Self-citationRhoden, A., Schulze, T., Pietsch, N., Christ, T., Hansen, A., & Eschenhagen, T. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00534.2021 · Cited by 21
Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy
Sebastian, S. A., Padda, I., Lehr, E. J., & Johal, G. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00599-0 · Cited by 21
Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF?
Kondo, T., Henderson, A. D., Docherty, K. F., Jhund, P. S., Vaduganathan, M., Solomon, S. D., & McMurray, J. J. V. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.033 · Cited by 20
Self-citationBánfi‐Bacsárdi, F., Pilecky, D., Vámos, M., Majoros, Z., Török, G. M., Borsányi, T., Dékány, M., Solymossi, B., Andreka, P. G., Duray, G. Z., et al. (2024) · Clinical Cardiology · doi:10.1002/clc.24244 · Cited by 20
Gu, Z., Liu, T., Rao, W., Li, D., Zhang, Q., Dai, J., Huang, L., Wang, J., & Hou, X. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202412335 · Cited by 20
The recent advance and prospect of natural source compounds for the treatment of heart failure
Chen, X.-J., Liu, S., Li, S., Feng, J.-K., Hu, Y. C., Cheng, X., Hou, C., Xu, Y., Hu, M., Ling, F., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27110 · Cited by 20
Parker, L. E., & Landstrom, A. P. (2021) · Progress in Pediatric Cardiology · doi:10.1016/j.ppedcard.2021.101413 · Cited by 20
Kaul, S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.036 · Cited by 19
Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction
Vishram‐Nielsen, J. K. K., Tomasoni, D., Gustafsson, F., & Metra, M. (2022) · Drugs · doi:10.1007/s40265-021-01666-z · Cited by 19
Self-citationKidney function assessment and endpoint ascertainment in clinical trials
Khan, M. S., Bakris, G. L., Packer, M., Shahid, I., Anker, S. D., Fonarow, G. C., Wanner, C., Weir, M. R., Zannad, F. M., & Butler, J. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab832 · Cited by 19
Self-citationOmecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future
Zhou, S., Liu, Y., Huang, X., Wu, C., & Pórszász, R. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1337154 · Cited by 19
Muk, B., Bánfi‐Bacsárdi, F., Vámos, M., Pilecky, D., Majoros, Z., Török, G., Vágány, D., Polgár, B., Solymossi, B., Borsányi, T., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14020131 · Cited by 19
The medical treatment of cardiogenic shock
Lescroart, M., Péquignot, B., Janah, D., & Lévy, B. (2023) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2022.12.001 · Cited by 19
Zaher, W., Rocca, D. G. D., Pannone, L., Bovéda, S., de Asmundis, C., Chierchia, G., & Sorgente, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051316 · Cited by 18
Ameri, P., Marzo, V. D., Biondi‐Zoccai, G., Tricarico, L., Correale, M., Brunetti, N. D., Canepa, M., Ferrari, G. M. D., Castagno, D., & Porto, I. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab088 · Cited by 18
Bhat, O. M., Mir, R. A., Nehvi, I. B., Wani, N. A., Dar, A. H., & Zargar, M. A. (2024) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2024.101469 · Cited by 18
Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis
Pagnesi, M., Baldetti, L., Aimo, A., Inciardi, R. M., Tomasoni, D., Vizzardi, E., Vergaro, G., Emdin, M., & Lombardi, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11020348 · Cited by 18
Chen, Y.-J., Chien, C., Chiang, C., Chen, C.-H., & Cheng, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126617 · Cited by 18
Avances en insuficiencia cardiaca
Zamorano, J. L., & Leal, A. G. (2024) · Medicina Clínica · doi:10.1016/j.medcli.2023.12.026 · Cited by 18
Chronic and acute decompensated heart failure: topical issues
Михайлович, О. И., Kochergina, A. M., & Кашталап, В. В. (2022) · Complex Issues of Cardiovascular Diseases · doi:10.17802/2306-1278-2022-11-2-184-195 · Cited by 18
Leancă, S. A., Afrăsânie, I., Crișu, D., Matei, I. T., Duca, Ș.-T., Costache, A. D., Aursulesei, V. O., Tudorancea, I., Mitu, O., Bădescu, M. C., et al. (2023) · Life · doi:10.3390/life13041000 · Cited by 18
Ráduly, A. P., Sárkány, F., Kovács, M. B., Bernát, B., Juhász, B., Szilvássy, Z., Pórszász, R., Horváth, B., Szentandrássy, N., Nánási, P. P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010446 · Cited by 18
Elsaeidy, A. S., Abuelazm, M. T., Ghaly, R., Soliman, Y., Amin, A. M., El-Gohary, M., Elshenawy, S., Seri, A. R., Abdelazeem, B., Patel, B. D., et al. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00675-z · Cited by 17
Metadata
- Authors
- Teerlink, J. R., Diaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I., Arias-Mendoza, A., Biering-Sørensen, T., Böhm, M., Bonderman, D., Cleland, J. G. F., Corbalan, R., Crespo-Leiro, M. G., Dahlström, U., Echeverria, L. E., Fang, J. C., Filippatos, G., Fonseca, C., Goncalvesova, E., Goudev, A. R., Howlett, J. G., Lanfear, D. E., Li, J., Lund, M., Macdonald, P., Mareev, V., Momomura, S.-I., O’Meara, E., Parkhomenko, A., Ponikowski, P., Ramires, F. J. A., Serpytis, P., Sliwa, K., Spinar, J., Suter, T. M., Tomcsanyi, J., Vandekerckhove, H., Vinereanu, D., Voors, A. A., Yilmaz, M. B., Zannad, F., Sharpsten, L., Legg, J. C., Varin, C., Honarpour, N., Abbasi, S. A., Malik, F. I., & Kurtz, C. E.
- Affiliations
- San Francisco VA Medical Center (US)
- From the Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California, San Francisco, San Francisco (J.R.T.), Amgen, Thousand Oaks (L.S., J.C.L., N.H., S.A.A., C.E.K.), and Cytokinetics, South San Francisco (F.I.M.) — all in California; Estudios Clínicos Latino América, Rosario, Argentina (R.D.); the Division of Cardiology, Duke University School of Medicine and Duke Clinical Research Institute, Durham (G.M.F.), and the University of North...
- Brigham and Women's Hospital (US)
- University of North Carolina at Chapel Hill (US)
- University of Minnesota (US)
- Linköping University (SE)
- University of Bern (CH)
- ORCID
- Teerlink, John R.
- Felker, G. Michael
- McMurray, John J.V.
- Metra, Marco
- Solomon, Scott D.
- Anand, Inder
- Böhm, Michael
- Bonderman, Diana
- Cleland, John G.F.
- Dahlström, Ulf
- Fang, James C.
- Filippatos, Gerasimos
- Fonseca, Cândida
- Goudev, Assen R.
- Howlett, Jonathan G.
- Lanfear, David E.
- Li, Jing
- Lund, Mayanna
- Macdonald, Peter
- Momomura, Shin-ichi
- O’Meara, Eileen
- Parkhomenko, Alexander
- Ponikowski, Piotr
- Sliwa, Karen
- Voors, Adriaan A.
- Zannad, Faiez
- Abbasi, Siddique A.
- Malik, Fady I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-01-14
- Volume
- 384
- Issue
- 2
- Pages
- 105-116
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3098430919
- Cited by
- 656
- References
- 26
- Citations by year
- 2026: 51 · 2025: 84 · 2024: 76 · 2023: 150 · 2022: 130 · 2021: 148
- FWCI
- 68.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- HAL (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Archive of Doctoral Theses and Digital Collections (University of Calabria) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- ORBi (University of Liège) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- RUC (Universidade Da Coruña) (submittedVersion)
- Funders
- Amgen
- Cytokinetics Inc.
- Servier
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- omecamtiv mecarbil, cardiac myosin activator, heart failure with reduced ejection fraction, cardiovascular outcomes, heart failure hospitalization, cardiovascular mortality, N-terminal pro-brain natriuretic peptide, cardiac troponin I, symptom burden, pharmacokinetic-guided dosing, ventricular arrhythmias
- MeSH terms
- Aged, Aged, 80 and over, Cardiotonic Agents, Cardiovascular Diseases, Female, Humans, Male, Middle Aged, Myocardial Contraction, Stroke Volume, Urea, Cardiac Myosins, Heart Failure, Systolic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.